Open AccessCan treatment with teicoplanin improve the prognosis of COVID‐19 patients?
Author(s) -
Yasar Zehra,
Yemisen Mucahit,
Yasar Huseyin,
Ertaş Aysun,
Meric Kaan,
Sahin Soner
Publication year - 2021
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.14752
Subject(s) - teicoplanin , medicine , covid-19 , adverse effect , retrospective cohort study , surgery , disease , infectious disease (medical specialty) , vancomycin , staphylococcus aureus , biology , bacteria , genetics
Aim In patients with COVID‐19, no validated efficient treatment has been reported. Herein, we examine the effect of treatment with teicoplanin in hospitalised patients with COVID‐19. Methods This retrospective study included 115 hospitalised patients in one medical centre. Fifty‐four patients with laboratory‐confirmed COVID‐19 who received teicoplanin plus standard care were included in the Teicoplanin arm of this study, whereas 61 patients who were treated with standard care (SC) according to the Turkish Health Organization guidelines were included in the control arm. Patients’ baseline characteristics, clinical presentation, treatment and outcomes were compared between the two groups. Results In this non‐randomised control study, all baseline characteristics were comparable between the two arms and there were no significant differences in the presenting symptoms, comorbidities and clinical outcomes between the two groups. However, the mortality rate was significantly lower in the teicoplanin group than in the control group (1.9% vs 14.8%; P < .05). In addition, no adverse reactions were found in the teicoplanin arm. Conclusions Teicoplanin administration is associated significantly with lower mortality in hospitalised patients with COVID‐19 in our study. Further clinical investigations is required to verify the role of teicoplanin in COVID‐19 patients.